Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Open accessAbstract
The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusion–positive cancers, including those with resistance mutations such as ROS1 G2032R. Download a PDF of the Research Summary. In this registrational phase 1–2 trial, we assessed the efficacy and safety of repotrectinib in patients with advanced solid tumors, including ROS1 fusion–positive NSCLC. The primary efficacy end point in the phase 2 trial was confirmed objective response; efficacy analyses included patients from phase 1 and phase 2. Duration of response, progression-free survival, and safety were secondary end points in phase 2. On the basis of results from the phase 1 trial, the recommended phase 2 dose of repotrectinib was 160 mg daily for 14 days, followed by 160 mg twice daily. Response occurred in 56 of the 71 patients (79%; 95% confidence interval [CI], 68 to 88) with ROS1 fusion–positive NSCLC who had not previously received a ROS1 TKI; the median duration of response was 34.1 months (95% CI, 25.6 to could not be estimated), and median progression-free survival was 35.7 months (95% CI, 27.4 to could not be estimated). Response occurred in 21 of the 56 patients (38%; 95% CI, 25 to 52) with ROS1 fusion–positive NSCLC who had previously received one ROS1 TKI and had never received chemotherapy; the median duration of response was 14.8 months (95% CI, 7.6 to could not be estimated), and median progression-free survival was 9.0 months (95% CI, 6.8 to 19.6). Ten of the 17 patients (59%; 95% CI, 33 to 82) with the ROS1 G2032R mutation had a response. A total of 426 patients received the phase 2 dose; the most common treatment-related adverse events were dizziness (in 58% of the patients), dysgeusia (in 50%), and paresthesia (in 30%), and 3% discontinued repotrectinib owing to treatment-related adverse events. Repotrectinib had durable clinical activity in patients with ROS1 fusion–positive NSCLC, regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. (Funded by Turning Point Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb; TRIDENT-1 ClinicalTrials.gov number, NCT03093116.) QUICK TAKE VIDEO SUMMARYRepotrectinib in ROS1 Fusion–Positive Lung Cancer 02:17
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Repotrectinib has CNS activity and was designed to be effective against ROS1 resistance mutations.
“Repotrectinib, recently FDA-approved for advanced ROS1+ NSCLC,9 has CNS activity and was designed to be effective against ROS1 resistance mutations.16,17”
From Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST (2025) · cites this paper as [17]
While repotrectinib is active against G2032R and brain metastases, a high incidence and wide spectrum of neurologic AEs were observed in most patients receiving repotrectinib.
“While active against G2032R and brain metastases, a high incidence and wide spectrum of neurologic adverse events (AEs) were observed in most patients receiving repotrectinib.9,17”
From Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST (2025) · cites this paper as [17]
Taletrectinib is a potential treatment option for patients with an ROS1 G2032R mutation.
“These data are comparable with responses seen with repotrectinib (ORR, 59%),17 suggesting that taletrectinib is a potential treatment option for patients with an ROS1 G2032R mutation.”
From Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005 · see citing works
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,971 · see citing works
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,506 · see citing works
Self-citationCSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S. S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 601 · see citing works
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576 · see citing works
Self-citationDrilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · see citing works
Self-citationShaw, A. T., Solomon, B., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S. C.-H., Lin, C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 359 · see citing works
Self-citationROS1-dependent cancers — biology, diagnostics and therapeutics
Drilon, A. E. D. C., Jenkins, C., Iyer, S. R., Schoenfeld, A. J., Keddy, C., & Davare, M. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0408-9 · Cited by 297 · see citing works
Self-citationGainor, J. F., Tseng, D., Yoda, S., Dagogo‐Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 269 · see citing works
Self-citationPatil, T., Smith, D. E., Bunn, P. A., Aisner, D. L., Le, A. T., Hancock, M., Purcell, W. T., Bowles, D. W., Camidge, D. R., & Doebele, R. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.001 · Cited by 205 · see citing works
Self-citationLin, J. J., Choudhury, N. J., Yoda, S., Zhu, V. W., Johnson, T. W., Sakhtemani, R., Dagogo-Jack, I., Digumarthy, S. R., Lee, C., Do, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0032 · Cited by 145 · see citing works
Self-citationYun, M. R., Kim, D. H., Kim, S., Joo, H.-S., Lee, Y. W., Choi, H. M., Park, C. W., Heo, S. G., Kang, H. N., Lee, S. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2777 · Cited by 122 · see citing works
Self-citationLong-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
Drilon, A., Chiu, C.-H., Fan, Y., Cho, B. C., Lu, S., Ahn, M.-J., Krebs, M. G., Liu, S. V., John, T., Otterson, G. A., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100332 · Cited by 113 · see citing works
Self-citationCharacterization of on-target adverse events caused by TRK inhibitor therapy
Liu, D., Flory, J., Lin, A. L., Offin, M. D., Falcon, C. J., Murciano‐Goroff, Y. R., Rosen, E. Y., Guo, R., Basu, E. M., Li, B. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.006 · Cited by 101 · see citing works
Self-citationMurray, B. W., Rogers, E., Zhai, D., Deng, W., Chen, X., Sprengeler, P. A., Zhang, X., Graber, A., Reich, S. H., Stopatschinskaja, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0632 · Cited by 89 · see citing works
Self-citationZhu, Q., Zhan, P., Zhang, X., Lv, T., & Song, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.05.01 · Cited by 61 · see citing works
Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0968 · Cited by 52 · see citing works
Self-citationInterpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
Coon, C. D., Schlichting, M., & Zhang, X. (2022) · Patient · doi:10.1007/s40271-022-00584-w · Cited by 33 · see citing works
Dziadziuszko, R., Hung, T., Wang, K., Choeurng, V., Drilon, A. E. D. C., Doebele, R. C., Barlési, F., Wu, C., Dennis, L. M., Skoletsky, J., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13214 · Cited by 21 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
New promises and challenges in the treatment of advanced non-small-cell lung cancer
Meyer, M., Fitzgerald, B. G., Paz-Ares, L. G., Cappuzzo, F., Janne, P. A., Peters, S., & Hirsch, F. R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01029-8 · Cited by 467 · see citing works
Update 2025: Management of Non‑Small-Cell Lung Cancer
Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 210 · see citing works
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197 · see citing works
Recent advances in therapeutic strategies for non-small cell lung cancer
Su, P., Furuya, N., Asrar, A., Rolfo, C. D., Li, Z., Carbone, D. P., & He, K. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01679-1 · Cited by 156 · see citing works
Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST
Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00275 · Cited by 63 · see citing works
Self-citationLung Cancer: Targeted Therapy in 2025
Bouchard, N., & Daaboul, N. (2025) · Current Oncology · doi:10.3390/curroncol32030146 · Cited by 62 · see citing works
Lung cancer research and treatment: global perspectives and strategic calls to action
Meyer, M., Peters, S., Mok, T. S. K., Lam, S. C., Yang, P., Aggarwal, C., Brahmer, J. R., Dziadziuszko, R., Felip, E., Ferris, A. A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.006 · Cited by 52 · see citing works
Self-citationOwen, D. H., Ismaila, N., Freeman‐Daily, J., Roof, L., Singh, N., Velázquez, A. I., & Leighl, N. B. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00762 · Cited by 49 · see citing works
Lung Cancer in Nonsmoking Individuals
Murphy, C., Pandya, T., Swanton, C., & Solomon, B. (2025) · JAMA · doi:10.1001/jama.2025.17695 · Cited by 55 · see citing works
Self-citationGenomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Marchetti, P., Curigliano, G., Biffoni, M., Lonardi, S., Scagnoli, S., Fornaro, L., Guarneri, V., de Giorgi, U., Ascierto, P., Blandino, G., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03918-x · Cited by 49 · see citing works
Weller, M., Remón, J., Rieken, S., Vollmuth, P., Ahn, M., Minniti, G. C., Rhun, É. L., Westphal, M., Brastianos, P. K., Soo, R. A., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102807 · Cited by 40 · see citing works
Li, W., Xiong, A., Yang, N., Fan, H., Yu, Q., Zhao, Y., Wang, Y., Meng, X., Wu, J., Wang, Z., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00731 · Cited by 40 · see citing works
Self-citationAdvances and future directions in <i>ROS1</i> fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38 · see citing works
Self-citationGautschi, O. P., Park, K., Solomon, B., Tomasini, P., Loong, H. H.-F., de Braud, F., Goto, K., Peterson, P. M., Barker, S. S., Liming, K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02076 · Cited by 32 · see citing works
Self-citationHendriks, L. E. L., Cortiula, F., Martins-Branco, D. A., Mariamidze, E., Popat, S., & Reck, M. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.06.007 · Cited by 32 · see citing works
Self-citationOncogenic gene fusions in cancer: from biology to therapy
Liu, S. V., Nagasaka, M., Atz, J., Solca, F., & Müllauer, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02161-7 · Cited by 31 · see citing works
Self-citationPuri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 35 · see citing works
Lee, S., Menis, J., Kim, T. M., Kim, H. R., Zhou, C., Kurniawati, S., Prabhash, K., Hayashi, H., Lee, D. D.-W., Imasa, M. S. B., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103996 · Cited by 33 · see citing works
Self-citationPancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
Mosalem, O. M., Abdelhakeem, A. A. F., Abdel-Razeq, N. H., & Babiker, H. M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473698 · Cited by 30 · see citing works
Top advances of the year: Targeted therapy for lung cancer
Makarem, M., & Janne, P. A. (2024) · Cancer · doi:10.1002/cncr.35423 · Cited by 29 · see citing works
Negrao, M. V., Paula, A. G., Molkentine, D. P., Hover, L. D., Nilsson, M. B., Vokes, N. I., Engstrom, L. D., Calinisan, A., Briere, D. M., Waters, L. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2310 · Cited by 32 · see citing works
Ou, S. I., Hagopian, G. G., Zhang, S. S., & Nagasaka, M. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.008 · Cited by 28 · see citing works
Self-citationFDA‐approved drugs featuring macrocycles or medium‐sized rings
Du, Y., Semghouli, A., Wang, Q., Mei, H., Kiss, L., Baecker, D., Soloshonok, V. A., & Han, J. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400890 · Cited by 28 · see citing works
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Besse, B., Lin, J. J., Bazhenova, L. A., Goto, K., Langen, A. J. D., Kim, D., Wolf, J., Springfeld, C., Popat, S., Lim, W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04079-7 · Cited by 25 · see citing works
Self-citationChang, A. E. B., Piper-Valillo, A. J., Mak, R. H., Lanuti, M. D., Muzikansky, A., Rotow, J. K., Janne, P. A., Mino-Kenudson, M. A., Swanson, S., Wright, C. D., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae107 · Cited by 25 · see citing works
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Bai, Y., Seng, D., Xu, Y. C., Zhang, Y., Zhou, W., Jia, Y.-Y., Song, J. Z., He, Z., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116706 · Cited by 24 · see citing works
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025) · Cancers · doi:10.3390/cancers17030353 · Cited by 26 · see citing works
Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
Desîlets, A., Repetto, M., Yang, S., & Drilon, A. (2025) · Cancer · doi:10.1002/cncr.35784 · Cited by 21 · see citing works
Self-citationPancreatic cancer in 2025: Have we found a solution?
Tonini, V., & Zanni, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i43.111433 · Cited by 21 · see citing works
Khan, S., Upadhyay, S., Kauser, S., Hasan, G. M., Lu, W., Waters, M., Hassan, M. I., & Sohal, S. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228021 · Cited by 17 · see citing works
Barbato, M. I., Bradford, D., Ren, Y., Aungst, S. L., Miller, C. P., Pan, L., Zirkelbach, J. F., Li, Y., Bi, Y., Fan, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0949 · Cited by 16 · see citing works
Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine
Ahmed, J., Torrado, C., Chelariu-Raicu, A., Kim, S., & Rodon, J. A. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00038 · Cited by 16 · see citing works
Self-citationLung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics
Wang, S., Uriel, M., & Cheng, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237371 · Cited by 16 · see citing works
NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy
Marczyk, V. R., Fazeli, S., Dadu, R., Busaidy, N. L., Iyer, P. C., Hu, M. I.-N., Sherman, S. I., Hamidi, S., Hosseini, S. M., Williams, M. D., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.24.00321 · Cited by 14 · see citing works
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A. A., Mithani, M. S., Anum, F., Asfeen, U. Z., Couch, J. K., Donovan, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311517 · Cited by 14 · see citing works
Navigating the Complexities of Brain Metastases Management
Amouzegar, A., Haig, S., Kahn, A. M., Tawbi, H. A., Jones, J., & Goldberg, S. B. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433694 · Cited by 14 · see citing works
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13 · see citing works
Self-citationNiho, S., Gotô, Y., Toyozawa, R., Daga, H., Ohashi, K., Takahashi, T., Tanaka, H., Sakakibara‐Konishi, J., Hattori, Y., Morise, M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103642 · Cited by 12 · see citing works
Self-citationAdvances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Hoang, T. A., & Tsang, E. S. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01149-w · Cited by 13 · see citing works
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 13 · see citing works
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review
Podder, V., Ranjan, T., Gowda, M., Camacho, A. M., & Ahluwalia, M. S. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01388-1 · Cited by 11 · see citing works
Current status of molecular diagnostics for lung cancer
Имянитов, Е. Н., Преображенская, Е. В., & Орлов, С. В. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00244 · Cited by 12 · see citing works
Koban, M. U., Hartmann, M., Amexis, G., Franco, P., Huggins, L., Shah, I., & Karachaliou, N. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0741 · Cited by 10 · see citing works
Desîlets, A., Repetto, M., & Drilon, A. E. D. C. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70017 · Cited by 10 · see citing works
Self-citationPrecision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?
Underwood, P. W., & Pawlik, T. M. (2024) · Cancers · doi:10.3390/cancers16223870 · Cited by 11 · see citing works
Wang, Z., Cai, G., Zhu, J., Wang, J., & Zhang, Y. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2837 · Cited by 10 · see citing works
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 10 · see citing works
Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates
Kim, J., Kim, H. S., Nam, M., & Chae, Y. K. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10274-2 · Cited by 10 · see citing works
Boldig, C. M., Boldig, K., Mokhtari, S., & Etame, A. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136961 · Cited by 10 · see citing works
Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer
Rais, T., Shakeel, A., Naseem, L., Nasser, N., & Aamir, M. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002717 · Cited by 9 · see citing works
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
Sun, Y., Ma, L., Zhang, X., & Wang, Z. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s487870 · Cited by 10 · see citing works
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
Waliany, S., Lin, J. J., & Gainor, J. F. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.005 · Cited by 9 · see citing works
Self-citationUnraveling the therapeutic landscape of approved non-peptide macrocycles
Li, Z., Zhang, Z., & Yu, B. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.021 · Cited by 10 · see citing works
Sampat, P. J., Cortese, A., Goodman, A., Ghelani, G. H., Mix, M. D., Graziano, S. L., & Basnet, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1411432 · Cited by 8 · see citing works
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
Tangpeerachaikul, A., Mente, S., Magrino, J., Gu, F., Horan, J. C., & Pelish, H. E. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0025 · Cited by 8 · see citing works
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology
Johnson, A., Shen, Y., Zheng, X., Su, F., Zeng, J., Uzunparmak, B., Breuer, E.-K. Y., Holla, V. R., Kahle, M., Kim, S.-H., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01110-1 · Cited by 9 · see citing works
Self-citationGlobal advances and future directions in lung cancer care: expert consensus and strategic priorities
Meyer, M.-L., Peters, S., Janne, P. A., Mok, T. S., Bunn, P. A., Karim, N. A., Altorki, N. K., Arrieta, O., Bar, J., Cappuzzo, F., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106034 · Cited by 11 · see citing works
Self-citationTaletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion–Positive Lung Cancer
Waliany, S., & Lin, J. J. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01062 · Cited by 8 · see citing works
Self-citationLeporati, R., Auclin, É., Morchón, D., Ferriol-Galmés, M., Laguna, J. C., Gorría, T., Teixidó, C., Amores, M., Ambrosini, P., Isla, D., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241306940 · Cited by 8 · see citing works
Current treatment and novel insights regarding ROS1 ‐targeted therapy in malignant tumors
Li, S., Zhang, H., Chen, T., Zhang, X., & Shang, G. (2024) · Cancer Medicine · doi:10.1002/cam4.7201 · Cited by 7 · see citing works
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors
Sheng, J., Chen, H., Fu, B., Pan, H., Wang, J., & Han, W. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00686-8 · Cited by 7 · see citing works
Post-translational modifications and the reprogramming of tumor metabolism
Hu, Y., Xu, W., & Chen, L. (2025) · Discover Oncology · doi:10.1007/s12672-025-02674-1 · Cited by 7 · see citing works
Rijmers, J., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.002 · Cited by 8 · see citing works
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race
Ashton, J. C. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117214 · Cited by 7 · see citing works
Advances in the Management of Lung Cancer Brain Metastases
Hockemeyer, K., Rusthoven, C. G., & Pike, L. (2024) · Cancers · doi:10.3390/cancers16223780 · Cited by 9 · see citing works
van der Wel, T. J. W. T., & Langen, A. J. D. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108490 · Cited by 6 · see citing works
Young lung cancer: from diagnosis to survivorship
Florez, N., Kiel, L., Kaufman, R. A., LoPiccolo, J., Ricciuti, B., Morabito, A. S., Fakorede, O., Mantz, C., Olazagasti, C., Swami, N. S., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570143 · Cited by 6 · see citing works
Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies
Urtecho, S. B., Munárriz, B., Rabey, M. R., & Leighl, N. B. (2025) · Cancers · doi:10.3390/cancers17213474 · Cited by 7 · see citing works
Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review
Bischoff, H., Gendarme, S., Somme, L., CHOUAID, C., & Schött, R. (2025) · Current Oncology · doi:10.3390/curroncol32110626 · Cited by 6 · see citing works
Güren, A. K., Kırcalı, M. F., Köstek, O., & Demircan, N. C. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2593540 · Cited by 6 · see citing works
Janžič, U., Rabinovich, N. M., Shalata, W., Kian, W., Szymczak, K., Dziadziuszko, R., Jakopović, M., Mountzios, G., Płużański, A., Araújo, A., et al. (2024) · Current Oncology · doi:10.3390/curroncol31080326 · Cited by 6 · see citing works
Self-citationMyall, N. J., & Das, M. S. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101133 · Cited by 6 · see citing works
Zhu, Y., He, D., Hou, Z., Lan, M., Zhang, Y., & Wang, Q. (2025) · Advanced Science · doi:10.1002/advs.202502626 · Cited by 5 · see citing works
Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer
Ahn, B., Kim, Y. J., Lee, Y. J., Suh, K. J., Kim, S. H., Kim, D.-W., Kim, T. M., Lee, K. H., & Han, J. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.5097 · Cited by 5 · see citing works
Self-citationDas, D., Xie, L., & Hong, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109617 · Cited by 5 · see citing works
Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology
Grossman, J. P., Sheppard, E. A., Yan, Z., Crabbe, M., & Punekar, Y. S. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00416-z · Cited by 5 · see citing works
Systemic Treatment of Thyroid Cancer: ASCO Guideline
Saba, N. F., Ismaila, N., Adkins, D. R., Agrawal, N., Akhave, N. S., Blomain, E. S., Cabanillas, M. E., Chen, A., Galloway, T. J., Harada, G., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00235 · Cited by 5 · see citing works
Zhong, H., Lü, J., Wang, M., & Han, B. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0043 · Cited by 5 · see citing works
Cai, W., Jiang, B., Yin, Y., Ma, L., Li, T., & Chen, J. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11067-5 · Cited by 5 · see citing works
Torresan, S., Bortolot, M., Carlo, E. D., Bertoli, E., Stanzione, B., Conte, A. D., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020554 · Cited by 6 · see citing works
Overview of systemic anticancer treatments: conventional cytotoxics
Zhang, B. (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2023.000059 · Cited by 5 · see citing works
Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist
Jafari, P., Forrest, M. E., Segal, J. P., Wang, P., & Tjota, M. Y. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100752 · Cited by 5 · see citing works
Wang, M., Yang, J., Wang, S., Gill, H., & Cheng, H. (2025) · Current Oncology · doi:10.3390/curroncol32030171 · Cited by 6 · see citing works
Weber, U., Davies, K. D., & Camidge, D. R. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100673 · Cited by 5 · see citing works
Self-citationClinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
Dekker, S. E., & Deng, L. (2024) · Cancers · doi:10.3390/cancers16223885 · Cited by 5 · see citing works
Zwierenga, F., Dijkhuizen, C., Korthuis, P. M., Timens, W., Groen, H. J. M., Hiltermann, T. J. N., van den Berg, A., Drayer, L., & van der Wekken, A. J. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70109 · Cited by 4 · see citing works
Advances in Computational Drug Repurposing, Driver Genes, and Therapeutics in Lung Adenocarcinoma
Nematzadeh, S., & Karaul, A. (2025) · Biomolecules · doi:10.3390/biom15101373 · Cited by 4 · see citing works
Yu, J., Zhu, M., Zhu, Y., & Shu, Q. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004704 · Cited by 4 · see citing works
Oncogenic influences of neurotrophin receptors: Shedding light on Trk biology
Jagana, H., Shabar, M., Jackson, T. S., Johnson, D. E., Hemenway, J., Mukkamala, V., Lukasik, A., Hathaway, M. R., & Pattwell, S. S. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116928 · Cited by 4 · see citing works
Hersey, S., McGuire, K., Kholmanskikh, O., Bivi, N., Bandukwala, A., Gong, B., Irwin, C. R., Ray, S., Gunsior, M., Avanesov, A. S., et al. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2599698 · Cited by 4 · see citing works
Feng, Y., Li, C., Cheng, B., Chen, Y., Chen, P., Wang, Z., Zheng, X., He, J., Zhu, F., Wang, W., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-65 · Cited by 4 · see citing works
Emerging Frontiers in the Treatment of Non-small Cell Lung Cancer: Innovations and Clinical Advances
An, Y., Zu, C., Zhuang, X., Zheng, X., Yasuda, Y., & Tang, M. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0024 · Cited by 4 · see citing works
Podder, V., Bellur, S. S., Margolin, K. A., Advani, P. P., Mahtani, R. L., Subbiah, V., Novo, G. B., Ranjan, T., & Ahluwalia, M. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01593-8 · Cited by 3 · see citing works
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
Wolf, J., Goring, S. M., Lee, A., Cho, B. C., Drilon, A. E. D. C., Yuan, Y., Ayers, D., Lozano‐Ortega, G., Korol, E. E., KORPACH, S. G. C., et al. (2025) · Cancers · doi:10.3390/cancers17050748 · Cited by 3 · see citing works
Self-citationTimeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis
Tanvetyanon, T., Joshi, U., Chen, D., & Gray, J. E. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00936 · Cited by 3 · see citing works
Fan, Y., Pan, W., Xiu, Q., Qiao, Y., Zhang, P., Liao, T., Feng, J., Nie, C., Chu, S., Li, N., et al. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.118032 · Cited by 3 · see citing works
Ma, Y., Song, Z., Chen, J., Zhao, Y., Fang, W., Guo, Y., Dong, Y., Yang, Y.-P., Wu, G., Fang, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103556 · Cited by 3 · see citing works
Camidge, D. R., Phillips, W. J., Nemenoff, R. A., & Cittelly, D. M. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.104 · Cited by 3 · see citing works
Self-citationWu, S.-G., & Chao-Chi, H. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.02.009 · Cited by 3 · see citing works
Calles, A., Alonso, M., Martín-Martorell, P., Gómez, A., de Castro, J., Martínez-Aguillo, M., Estival, A., Mosquera, J., Martínez-Banaclocha, N., Majem, M., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100905 · Cited by 3 · see citing works
- Authors
- Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., Lee, K. H., Popat, S., Springfeld, C., Nagasaka, M., Felip, E., Yang, N., Velcheti, V., Lu, S., Kao, S., Dooms, C., Krebs, M. G., Yao, W., Beg, M. S., Hu, X., Moro-Sibilot, D., Cheema, P., Stopatschinskaja, S., Mehta, M., Trone, D., Graber, A., Sims, G., Yuan, Y., & Cho, B. C.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) — all in New York; the University of Colorado, Anschutz Medical Campus, Aurora (D.R.C.); Massachusetts General Hospital, Harvard Medical School, Boston (J.J.L.); Asan Medical Center (S.-W.K.) and Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Seoul, and Chungbuk National University Hospital, Cheongju-si (K.H.L.) — all in South Korea; the Peter MacCallum Cancer Center, Melbourne, VIC (B.J.S.), and the Chris O’Brien Lifehouse, Camperdown, NSW (S.K.) — both in Australia; the Department of Oncology and Radiotherapy and Early Clinical Trials Center, Medical University of Gdansk, Gdansk, Poland (R.D.); Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif (B.B.), and Centre Hospitalier Universitaire de Grenoble–Alpes, La Tronche (D.M.-S.) — both in France; National Cancer Center Hospital East, Kashiwa, Japan (K.G.); the Netherlands Cancer Institute, Am...
- Royal Marsden NHS Foundation Trust (GB)
- ORCID
- Drilon, Alexander
- Camidge, D. Ross
- Lin, Jessica J.
- Kim, Sang-We
- Solomon, Benjamin J.
- Besse, Benjamin
- Wolf, Jürgen
- Lee, Ki Hyeong
- Popat, Sanjay
- Springfeld, Christoph
- Nagasaka, Misako
- Felip, Enriqueta
- Yang, Nong
- Velcheti, Vamsidhar
- Kao, Steven
- Dooms, Christophe
- Krebs, Matthew G.
- Yao, Wenxiu
- Beg, Muhammad Shaalan
- Cheema, Parneet
- Sims, Gregory
- Yuan, Yong
- Cho, Byoung Chul
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-11
- Volume
- 390
- Issue
- 2
- Pages
- 118-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11702311
- OpenAlex
- W4390690905
- Cited by
- 240
- References
- 19
- Citations by year
- 2026: 94 · 2025: 91 · 2024: 54 · 2023: 1
- FWCI
- 69.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Manchester Biomedical Research Centre
- National Cancer Institute (1R01CA273224-01, P30 CA008748)
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- repotrectinib, ROS1 rearrangement, non-small cell lung cancer, ROS1 tyrosine kinase inhibitors, acquired resistance, intracranial activity, progression-free survival, objective response rate, treatment-related adverse events, advanced solid tumors, recommended phase 2 dose, duration of response, dizziness
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Pyrazoles, Treatment Outcome, Macrocyclic Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
